Press Releases

 
Press Releases
  Date Title View
Dec 7, 2004
South San Francisco, CA, December 7, 2004 - Theravance, Inc. (NASDAQ: THRX) today announced results from FAST 2, a Phase 2 clinical study with the investigational antibiotic telavancin (TD-6424). FAST 2 was a randomized, double blind, multinational study of intravenous telavancin dosed once a day or standard therapy (vancomycin dos...
Nov 3, 2004
Theravance, Inc. Reports Third Quarter 2004 Financial ResultsTheravance, Inc. Reports Third Quarter 2004 Financial Results Initiated Telavancin Phase 3 Clinical Studies Completed Initial Public Offering SOUTH SAN FRANCISCO, CA ...
Nov 2, 2004
Theravance Announces Results From Pre-clinical And Clinical Studies With Investigational Antibiotic Telavancin South San Francisco, CA, November 2, 2004 - Theravance, Inc. (NASDAQ: THRX) announced today that results from a Phase 2 clinical study with the investigational antibiotic telavancin (TD-6424) in patients with complicated ...
Oct 19, 2004
SOUTH SAN FRANCISCO, CA / October 19, 2004 - Theravance, Inc. (Nasdaq: THRX) announced today that it will release financial results for the period ended September 30, 2004 after market close on Wednesday, November 3, 2004 with an accompanying conference call at 5:00 p.m. EST. To participate in the live call by telephone, please dial 8...
May 11, 2004
SOUTH SAN FRANCISCO, CA / May 11, 2004 -- Theravance, Inc., a privately-held pharmaceutical company, announced today that the strategic alliance with GlaxoSmithKline (GSK), previously announced on March 31st, was consummated and funded after receiving the requisite regulatory and Theravance shareholder approvals. This innovative broad-based strateg...
May 11, 2004
South San Francisco, CA, May 11, 2004 - Theravance, Inc. announced today that results from a series of four in vitro and in vivo studies as well as human clinical studies with the investigational antibiotic telavancin (TD-6424) were presented at the 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Prague. ...
Mar 31, 2004
LONDON, UK and SOUTH SAN FRANCISCO, CA / March 31, 2004 -- GlaxoSmithKline plc (GSK) and Theravance, Inc., a privately-held pharmaceutical company, announced today that they have entered into an innovative broad-based strategic alliance to develop and commercialize novel medicines across a variety of important therapeutic areas, including bacterial...
Dec 3, 2003
SOUTH SAN FRANCISCO, CA December 3, 2003/ PR Newswire/ -- Theravance, Inc. announced today that the lead compounds in its alliance with GlaxoSmithKline (GSK) to identify new long-acting, beta2-agonists (LABAs) for the treatment of respiratory diseases, GSK 159797 and GSK 597901, have demonstrated positive results in two recently-completed, early P...
Nov 24, 2003
SOUTH SAN FRANCISCO, Calif., November 24, 2003 /PRNewswire/ -- Theravance, Inc., today announced that results from a study with its investigational intravenous pharmacokinetically-responsive sedative hypnotic THRX-918661 were recently presented at the 2003 Meeting of the American Society of Anesthesiologists Annual Meeting in San Francisco. The st...
Sep 24, 2003
SOUTH SAN FRANCISCO, CA Date: September 24, 2003 Theravance, Inc., today announced that results from a series of eleven in vitro, in vivo, and human clinical studies with the investigational antibiotic TD-6424 were presented at the 43rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chi...
FirstPrevious
...
35
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$13.45 0.02 (0.15%) 12/13/17 1:50 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.